(Health Korea News / Lee Si-woo) Hanmi Pharmaceutical announced that it will achieve sales of 5 trillion won within the next 10 years by accelerating growth led by innovative new drugs. By 2033, it will be 2.2 trillion won domestically and 3 trillion won overseas and in other fields. The goal of achieving operating profit is 1 trillion won.
Hanmi Pharmaceutical unveiled its core tasks and mid- to long-term growth strategies that reflect this vision at a corporate information session for analysts and institutional investors held at the Fairmont Ambassador Hotel in Yeouido, Seoul on the 11th.
According to the data released on this day, the mid- to long-term strategic direction is ▲Phase 1 (’24~’25) Achieving a super gap in the domestic market and laying the foundation for entry into the global market ▲Phase 2 (’26~’28) Increasing sales of innovative new drugs/combined new drugs , Strengthening global business capabilities ▲Phase 3 (’29~’33) Accelerating growth led by innovative new drugs, sales of KRW 5 trillion within 10 years (KRW 2.2 trillion domestically in ’33, Overseas/others: KRW 3 trillion) and operating profit: KRW 1 trillion.
To this end, Hanmi Pharmaceutical established and presented the roles and detailed action tasks for each department.
First, the domestic business division will strengthen its evidence-based marketing and patient-tailored treatment strategy and achieve its domestic business target of KRW 1.7 trillion in sales by 2028 by taking the overwhelming first place in domestic M/S (Market Share) and launching innovative new drugs. This is a plan to achieve.
The New Product Development Division and Pharmaceutical Research Institute have developed new indications, including new usage and dosage, and planned to launch new products for continuous market development.
The R&D Center aims to build a pipeline according to the first-in class strategy with a new modality and enhance the value of new drugs through licensing out and in-house development, while the Global Headquarters aims to globalize the Hanmi Brand and strengthen the global market capabilities of new drugs and new products. .
An official from Hanmi Pharmaceutical said, “Today’s event is not about governance issues, but an opportunity to share Hanmi Pharmaceutical’s original business performance and future plans.” He added, “There will be no separate questions and answers regarding governance, but rather a time to present and answer questions about business performance and vision.” “We proceeded with it,” he said.
Hanmi Pharmaceutical expects that this information session will be an opportunity to fully highlight the future value of Hanmi Pharmaceutical, which has been obscured by the protracted management rights issue.
“An opportunity to shed light on the future value of Hanmi Pharmaceutical, which was obscured by management rights issues.”
Achieved 1 trillion won in outpatient prescriptions for the first time among domestic pharmaceutical companies and ranked first for 6 consecutive years
In fact, Hanmi Pharmaceutical showed its potential last year by becoming the first domestic pharmaceutical company to achieve 1 trillion won in outpatient prescriptions and to rank first for six consecutive years. There are 22 blockbuster products with sales of more than 10 billion won, including ‘Rosujet’, a combination new drug for the treatment of dyslipidemia. This is an increase of 4 items compared to 2022.
We established a bridgehead for overseas expansion (Eurasia, Central and South America, etc.) by pioneering new markets and business channels for finished products such as ‘Gugutams’, a combination treatment for benign prostatic hyperplasia and erectile dysfunction, and improved bioplant operation rate and strengthened profitability by expanding production of ‘Rolontis’.
Beijing Hanmi’s performance is also encouraging. Beijing Hanmi Pharmaceutical is a local company jointly established in 1996 by Hanmi Pharmaceutical and Hualun Jia Pharmaceutical, a Chinese state-owned enterprise. It is a key subsidiary of Hanmi Pharmaceuticals, recording annual sales of 400 billion won based on specialized products such as lactic acid colonizer ‘Mamiai’, cough medicine for children ‘Etanjing’, and cough expectorant for adults ‘Ianping’.
Thanks to these performances, Beijing Hanmi has maintained double-digit sales growth and an operating profit ratio in the 20% range every year since the pandemic. Beijing Hanmi, in particular, operates its own R&D laboratory and is contributing to Hanmi’s new drug development. The candidate substance ‘BH3120’, using the independently developed bispecific antibody platform ‘Pentambody’, is undergoing phase 1 clinical trials in the United States and Korea.
(Refer to the mid- to long-term growth strategy report below)
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
